Real-life outcomes of tenofovir disoproxil fumarate monotherapy in nucleos(t)ide analogue-naive and nucleos(t) ide analogue-experienced chronic hepatitis B patients: A single-center experienc

• Published in: Viral hepatit dergisi 2016, Vol.22 (3), p.92-96
• Main Authors: Toka,Onur, Korkmaz,Pınar, Çevik Çağan,Figen, Aykın,Nevil, Naz,Hasan
• Format: Article
• Language: English
• Subjects: Tıp
• ISSN: 1307-9441; 2147-2939
• DOI: 10.4274/vhd.94830

Objective: The aim of the study was to evaluate the long-term results of treatment efficacy and safety in nucleos(t)ide analogue-naive (NA-naive) and NA-experienced chronic hepatitis B (CHB) patients receiving tenofovir disoproxil fumarate (TDF) therapy. Materials and Methods: Data of 99 patients treated with the diagnosis of CHB (hepatitis B surface antigen-positive for more than 6 months) with TDF monotherapy between February 2008 and May 2014 were evaluated retrospectively. Results: In total, 99 patients (median age: 50 years, 68.7% male, 21.2% hepatitis B e-antigen-positive) were included in the study. Thirty patients were NA-naive and 69 patients were NA-experienced. No significant difference was determined between NA-naive and NA-experienced patients regarding the rate of achieving complete virological response at the 1st, 2nd, 3rd, 4th, and 5th years of the treatment (p>0.05). Additionally, no significant difference was determined between NA-naive and NA-experienced patients regarding achieving a biochemical response rate at the 1st, 2nd, 3rd, 4th, and 5th years of the treatment (p>0.05). In our study, resistance at the end of the 5th year was not found. No patient required discontinuation of the treatment due to adverse effects during treatment. Conclusion: Data analysis indicates that TDF monotherapy provides an efficient viral suppression in NA-naive and NA-experienced patients at the end of the 5th year of the treatment.